Lupus Trials
The Division of Rheumatology strives to understand more about lupus through research. Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease.
| Study Name/IRB#/PI | Brief Description | Basic Eligibility Criteria | Contact |
UCB IRB#25-0664 | A Phase 3 Placebo controlled study evaluating the safety and effectiveness of Dapirolizumab Pegol for the treatment of active Systemic Lupus Erythematosus (SLE) |
| Chong Pedrick 303-727-8948 |
BreakFree - CAR-T study in SLE, IIM and SSc 24-0289 Melissa Griffith, MD | A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants with Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, idiopathic Inflammatory Myopathy or Systemic Sclerosis |
|
Primary Contact: 303-724-8948 |
Break-Free - SLE IRB# 25-0407 Melissa Griffith, MD | A Phase 2, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE) |
| Primary Contact: 303-724-8948 [email protected] |
Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length. A visit to determine an individuals eligibility may be required. A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.